Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Black Diamond gets $85mm in Series B money

Executive Summary

Just one month after announcing its $20mm Series A round from Versant Ventures, cancer drug developer Black Diamond Therapeutics Inc. revealed that it raised $85mm through a Series B round from co-lead investors New Enterprise Associates and RA Capital, along with NexTech Invest, Invus Group, and Perceptive Advisors. Versant also took part in the current round. Black Diamond is using its MAP (mutation, allostery and pharmacology) platform to identify and drug allosteric mutant disease targets, and will put the venture funding towards advancement of a few lead candidates into clinical trials (including programs targeting EGFR and HER2 allosteric mutants), and also towards establishment of new corporate headquarters in Cambridge, MA.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies